USD0.000æéå€ååŒÂ  (ET)
268.87MæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
86.520å§å€
90.400é«å€
74.06Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
æå€±é¡äºæ³PER
--çŽè¿12ã¶æé
åœ
2.27%売買å転ç
85.190忥çµå€
82.250å®å€
2.89M売買代é
æå€±é¡æ ªäŸ¡åçç
5.23PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-18.63%ç·è³ç£å©çç
97.97052é±é«å€
1.37åºæ¥é«æ¯ç%
-10.58MçŽå©ç
3.27Mæ ªåŒæ°
-2.19931æ ªåœããå©çïŒEPSïŒ
1.15ããŒã¿å€
-23.72%èªå·±è³æ¬å©çç
6.80052é±å®å€
9.57%æ¯ãå¹
100.00%ç²å©çç
268.87MæäŸ¡ç·é¡
2.34ãªã¹ã¯ãªã¿ãŒã³
6.39%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Sol Gel Technologies Ltdã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž109äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯193.00ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯è¯å¥œã§ããã¡ã³ãã¡ã³ã¿ã«ãºãåªããŠããŸãããããã¯ãã«ã«ã¯çŸåšã®ãã¬ã³ããè£ä»ãããã®ã§ã¯ãããŸãããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Sol Gel Technologies Ltdã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Sol Gel Technologies Ltdã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Sol Gel Technologies Ltd ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
Sol Gel Technologies Ltd
SLGL
4
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
ææšî
ææš
売ã(2)
äžç«(4)
è²·ã(1)
ç§»åå¹³å
売ã(2)
äžç«(0)
è²·ã(4)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Sol Gel Technologies Ltdã®äŒæ¥æ
å ±î
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Companyâs offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
äŒæ¥ã³ãŒãSLGL
äŒæ¥åSol Gel Technologies Ltd
æé«çµå¶è²¬ä»»è
ãCEOã
ãŠã§ããµã€ãhttp://www.sol-gel.com
æ ªäž»çµ±èšî
ãããã質å
Sol Gel Technologies LtdïŒSLGLïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îSol Gel Technologies LtdïŒSLGLïŒã®çŸåšã®æ ªäŸ¡ã¯82.25ã§ãã
Sol Gel Technologies Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îSol Gel Technologies Ltdã®ãã£ãã«ãŒã·ã³ãã«ã¯SLGLã§ãã
Sol Gel Technologies Ltdã®52é±é«å€ã¯ãããã§ããïŒ
îSol Gel Technologies Ltdã®52é±é«å€ã¯97.97ã§ãã
Sol Gel Technologies Ltdã®52é±å®å€ã¯ãããã§ããïŒ
îSol Gel Technologies Ltdã®52é±å®å€ã¯6.80ã§ãã
Sol Gel Technologies Ltdã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îSol Gel Technologies Ltdã®æäŸ¡ç·é¡ã¯268.87Mã§ãã
Sol Gel Technologies Ltd (SLGL) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãSol Gel Technologies LtdïŒSLGLïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯193.00ã§ãã
Sol Gel Technologies Ltd (SLGL) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îSol Gel Technologies LtdïŒSLGLïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-2.20ã§ãã